Hypersensitvity reactions to etoposide

Annals of Pharmacotherapy

Volumn 30, Issue 4, 1996, Pages 367-371

  Hoetelmans, Richard M W ^a   Schornagel, Jan H ^b   Ten Bokkel Huinink, Wim W ^c   Beijnen, Jos H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BLEOMYCIN; CISAPRIDE; CISPLATIN; CORTICOSTEROID; ETOPOSIDE; GRANISETRON;

ADULT; ALOPECIA; ARTICLE; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; TESTIS CARCINOMA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG HYPERSENSITIVITY; ETOPOSIDE; HUMANS; HYPERSENSITIVITY, DELAYED; MALE;

EID: 0029921747     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000409     Document Type: Article

References (25)

1. Henwood JM, Brogden RN. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer Drugs 1990;39:438-90.
2. Gell PHG, Coombs RRA. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PHG, Coombs RRA. Lachmann PJ, eds. Clinical aspects of immunology 3rd ed. London: Blackwell Scientific Publications, 1975:761-81.
3. O'Dwyer PJ, Weiss RB. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 1984;68:959-61.
4. Walther PJ, Williams SD. Troner M, Greco FA, Birch R, Einhorn LH, et al. Phase II study of etoposide for carcinoma of the bladder: the South-eastern Cancer Study Group experience. Cancer Treat Rep 1986;70:1337-8
5. Young CW, Ihde DC, Von Stubbe W. Preliminary clinical trial of 4′-demethylepipodophyllotoxin-ß-D-ethylidene-glucoside (VP 16-213) (abstract). Proc Am Assoc Cancer Res 1973;14:60.
6. Kellie SJ, Gist WM, Pui CH, Crone ME, Fairclough DL, Rodman JH, et al. Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukaemia. Cancer 1991;67:1070-5.
7. Hudson MM, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993;11:1080-4.
8. Friedland D, Gorman G, Treat J. Hypersensitivity reactions from taxol and etoposide (letter). J Natl Cancer Inst 1993;85:2036.
9. Kasperek C, Black CD. Two cases of suspected immunologic-based hypersensitivity reactions to etoposide therapy. Ann Pharmacother 1992;26:1227-30.
10. Athanassiou AE, Bafaloukos D, Pectasidis D, Dimitriadis M. Acute vasomotor response - a reaction to etoposide J Clin Oncol 1988;6:1204-5.
11. Cersosimo RJ, Calarese P, Karp DD. Acute hypotensive reaction to etoposide with successful rechallenge: case report and review of the literature. DICP Ann Pharmacother 1989;23:876-7.
12. Jameson CH, Solanki DL. Stevens-Johnson syndrome associated with etoposide therapy. Cancer Treat Rep 1983,67:1050-1.
13. Kung F, Hayes FA, Krischer J, Mahoney D Jr, Leventhal B, Brodeur G, et al. Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Invest New Drugs 1988;6:31-6.
14. Nissen NI, Pajak TF, Leone LA, Bloomfield CD, Kennedy BJ, Ellison RR, et al. Clinical trial of VP 16-213 (NSC 141540) i.v. twice weekly in advanced neoplastic disease. A study by the Cancer and Leukaemia Group B. Cancer 1980;45:232-5.
15. Ogle KM, Kennedy BJ. Hypersensitivity reactions to etoposide. A case report and review of the literature. Am J Clin Oncol 1988;11:663-5.
16. De Souza P, Friedlander M, Wilde C, Kirsten F, Ryan M. Hypersensitivity reactions to etoposide. A report of three cases and review of the literature. Am J Clin Oncol 1994;17:387-9.
17. Sutherland CM, Loufti A. Unusual reaction to VP-16-213 and avoidance by prolonged mfusion (letter). Cancer Treat Rep 1982;66:409.
18. Tester WJ, Cohn JB, Fleekop PD, Rabinowitz MS, Lieberman JS. Successful rechallenge to etoposide after an acute vasomotor response. J Clin Oncol 1990,8:1600-1.
19. Tucci E, Pirtoli L. Etoposide-induced hypersensitivity reactions. Report of two cases. Chemioterapia 1985;4:460-2.
20. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992;19:458-77.
21. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981;94:66-72.
22. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988;21:246-50.
23. Nolte H, Carstensen H, Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol 1988;10:308-12.
24. Parish RC, Miller LJ. Nedocromil sodium. Ann Pharmacother 1993;27:599-606.
25. King HC. Mast cell stabilizers. Otolaryngol Head Neck Surg 1992;107:841-4.